Integrated Treatment for Enhancing Growth in Recovery During Adolescence (NCT06395467)
Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA)
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a Phase II parallel group randomized controlled trial with 294 adolescents (age: 14-21 years) with alcohol and other drug \[AOD\] use disorder (hereafter substance use disorder), that compares two different active psychosocial interventions designed to address adolescent substance use disorder. Participants are recruited from our clinical settings and the community at two sites: one in the metro Boston, Massachusetts (MA) area and the other in the metro Farmington, Connecticut (CT), area. Study aims and hypotheses are as follows: 1. To extend the evidence for the initial efficacy of Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA), which integrates 12-Step Facilitation (TSF) with Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT) relative to gold standard MET/CBT alone (N = 294). It is hypothesized that youth assigned to InTEGRA will have greater 12-step participation during and following treatment, higher abstinence rates, and fewer substance-related negative consequences. 2. Investigate the personal recovery capital (PRC) and social recovery capital (SRC) mechanisms of behavior change through which InTEGRA may confer benefits dynamically over time (e.g., PRC: motivation, self-efficacy, coping; SRC: 12-step involvement; social network changes). 3. Investigate moderators of InTEGRA's effects on outcomes across one-year follow-up (e.g., effect of age, network support for AOD use; psychiatric severity; age composition of 12-step meetings on substance use and substance-related consequences). It is hypothesized that higher network support for AOD use, abstinence motivation, and greater AOD severity, will have a better response to InTEGRA. 4. Explore barriers and facilitators to InTEGRA adoption and implementation across providers and system administrators within the context of a type I hybrid effectiveness-implementation research design.
Who can join: Review the eligibility criteria below.
Location: UConn Health โ Farmington, Connecticut
Age range: 14 Years to 21 Years
๐งช Interventions in This Study
- InTEGRA (BEHAVIORAL)
- MET/CBT (BEHAVIORAL)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (2 Sites)
- UConn Health โ Farmington, Connecticut
- MGH Department of Psychiatry โ Boston, Massachusetts
๐ Contact the Study Coordinator
Phone: (617) 724-5259
Email: aabry@mgh.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alcohol Use Disorder
- Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism โ Portland, Oregon
- Alcoholic Liver Disease and the Gut Microbiome โ Los Angeles, California
- Telehealth Treatment for Alcohol Use Disorder โ Stanford, California
- Remote Alcohol Monitoring to Facilitate Abstinence From Alcohol: Exp 1 โ Lexington, Kentucky
- Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder โ Iowa City, Iowa
- rTMS in Older Adults With MCI and AUD โ Charleston, South Carolina
Explore by condition: All Alcohol Use Disorder clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.